IB
Union Calendar No. 78
107TH CONGRESS
1ST SESSION
H. R. 2069
[Report No. 107–137]
To amend the Foreign Assistance Act of 1961 to authorize assistance to
prevent, treat, and monitor HIV/AIDS in sub-Saharan African and other
developing countries.
IN THE HOUSE OF REPRESENTATIVES
JUNE 6, 2001
Mr. HYDE introduced the following bill; which was referred to the Committee
on International Relations
JULY 12, 2001
Additional sponsors: Mr. LANTOS, Ms. MILLENDER-MCDONALD, Mr. HOUGH-
TON, Mr. KING, Mrs. MINK of Hawaii, Mrs. MORELLA, Mrs. MCCARTHY
of New York, Mr. GILMAN, Mr. GALLEGLY, Mr. COOKSEY, Mr.
TANCREDO, Mr. SMITH of New Jersey, Ms. ROS-LEHTINEN, Mr. KIRK,
Mr. CANTOR, Mr. EHRLICH, Ms. LEE, Mrs. NAPOLITANO, Mr. LEACH,
Mr. WEXLER, and Mr. BLUMENAUER
JULY 12, 2001
Reported with an amendment, committed to the Committee of the Whole
House on the State of the Union, and ordered to be printed
[Strike out all after the enacting clause and insert the part printed in italic]
[For text of introduced bill, see copy of bill as introduced on June 6, 2001]
A BILL
To amend the Foreign Assistance Act of 1961 to authorize
assistance to prevent, treat, and monitor HIV/AIDS in
sub-Saharan African and other developing countries.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ‘‘Global Access to HIV/
AIDS Prevention, Awareness, Education, and Treatment
Act of 2001’’.
SEC. 2. FINDINGS; SENSE OF CONGRESS.
(a) FINDINGS.—Congress makes the following findings:
(1) According to the Joint United Nations Pro-
gramme 
on 
HIV/AIDS 
(UNAIDS) 
more 
than
58,000,000 people worldwide have already been in-
fected with HIV/AIDS, a fatal disease that is dev-
astating the health and economies in dozens of coun-
tries in Africa and increasingly in Asia, the Carib-
bean region, and Eastern Europe.
(2) The HIV/AIDS pandemic has erased decades
of progress in improving the lives of families in the
developing world and has claimed 22,000,000 lives
since its inception.
(3) More than 17,000,000 individuals have died
from HIV/AIDS in sub-Saharan Africa alone.
(4) The HIV/AIDS pandemic in sub-Saharan
Africa has grown beyond an international public
health issue to become a humanitarian, national secu-
rity, and developmental crisis.
(5) The HIV/AIDS pandemic is striking hardest
among women and girls. According to UNAIDS, by
the end of 2000, fifty-five percent of the HIV-positive
population in sub-Saharan Africa and 40 percent of
such population in North Africa and the Middle East
were women, infected mainly through heterosexual
transmission. In Africa, 6 out of 7 children who are
HIV positive are girls.
(6) An estimated 1,400,000 children under age
15 were living with HIV/AIDS at the end of 2000, of
which 1,100,000 were children living in sub-Saharan
Africa. An estimated 500,000 children died of AIDS
during 2000, of which 440,000 were children in sub-
Saharan Africa. In addition there are an estimated
13,200,000 children worldwide who have lost one or
both of their parents to HIV/AIDS, of which
12,100,000 are children in sub-Saharan Africa.
(7) Mother-to-child transmission is the largest
source of HIV infection in children under age 15 and
the only source for very young children. The total
number of births to HIV-infected pregnant women
each year in developing countries is approximately
700,000.
(8) Counseling and voluntary testing are critical
services to help infected women accept their HIV sta-
tus and the risk it poses to their unborn child. Moth-
ers who are aware of their status can make informed
decisions about treatment, replacement feeding, and
future child-bearing.
(9) Although the HIV/AIDS pandemic has im-
pacted the sub-Saharan Africa disproportionately,
HIV infection rates are rising rapidly in India and
other South Asian countries, Brazil, Russia, Eastern
European countries, and Caribbean countries, and
pose a serious threat to the security and stability in
those countries.
(10) By 2010, it is estimated that approximately
40,000,000 children worldwide will have lost one or
both of their parents to HIV/AIDS.
(11) In January 2000, the United States Na-
tional Intelligence Council estimates that this dra-
matic increase in AIDS orphans will contribute to
economic decay, social fragmentation, and political
destabilization in already volatile and strained soci-
eties. Children without care or hope are often drawn
into prostitution, crime, substance abuse or child sol-
diery. The Council also stated that, in addition to the
reduction of economic activity caused by HIV/AIDS
to date, the disease could reduce GDP by as much as
20 percent or more by 2010 in some countries in sub-
Saharan Africa.
(12) The HIV/AIDS epidemic is not just a
health crisis but is directly linked to development
problems, including chronic poverty, food security
and personal debt that are reflected in the capacity
of affected households, often headed by elders or or-
phaned children, to meet basic needs. Similarly, heav-
ily-indebted countries are stripped of the resources
necessary to improve health care delivery systems and
infrastructure and to prevent, treat, and care for in-
dividuals affected by HIV/AIDS.
(13) On March 7, 2001, the United States Sec-
retary of State testified before Congress that the
United States has an obligation ‘‘ . . . if we believe
in democracy and freedom, to stop this catastrophe
from destroying whole economies and families and so-
cieties and cultures and nations’’.
(14) A continuing priority for responding to the
HIV/AIDS crisis should be to emphasize and encour-
age awareness, education, and prevention, including
prevention activities that promote behavioral change,
while recognizing that behavioral change alone will
not conquer this disease. In so doing, priority and
support should be given to building capacity in the
local public health sector through technical assistance
as well as through nongovernmental organizations,
including faith-based organizations where practicable.
(15) Effective use should be made of existing
health care systems to provide treatment for individ-
uals suffering from HIV/AIDS.
(16) Many countries in Africa facing health cri-
ses, including high HIV/AIDS infection rates, already
have well-developed and high functioning health care
systems. Additional resources to expand and improve
capacity to respond to these crises can easily be ab-
sorbed by the private and public sectors, as well as by
nongovernmental organizations, community-based or-
ganizations, and faith-based organizations currently
engaged in combatting the crises.
(17) An effective response to the HIV/AIDS pan-
demic must also involve assistance to stimulate the
development of sound health care delivery systems and
infrastructure in countries in sub-Saharan Africa
and other developing countries, including assistance
to increase the capacity and technical skills of local
public health professionals and other personnel in
such countries, and improved access to treatment and
care for those already infected with HIV/AIDS.
(18) Access to effective treatment for HIV/AIDS
is determined by issues of price, health care delivery
system and infrastructure, and sustainable financing
and such access can be inhibited by the stigma and
discrimination associated with HIV/AIDS.
(19) The HIV/AIDS crisis must be addressed by
a robust, multilateral approach. The Secretary Gen-
eral of the United Nations has called for a global fund
to halt and reverse the spread of HIV/AIDS and other
infectious diseases. The Secretary General has also
called for annual expenditures of $7,000,000,000 to
$10,000,000,000, financed by donor governments and
private contributors, for all efforts to combat the HIV/
AIDS pandemic and, equally important, called on
leaders from developing countries to give a much
higher priority in their budgets to development of
comprehensive health systems.
(20) An effective United States response to the
HIV/AIDS crisis must also focus on the development
of HIV/AIDS vaccines to prevent the spread of the
disease as well as the development of microbicides, ef-
fective diagnostics, and simpler treatments.
(21) The innovative capacity of the United
States in the commercial and public pharmaceutical
research sectors is among the foremost in the world,
and the active participation of both these sectors
should be supported as it is critical to combat the
global HIV/AIDS pandemic.
(22) Appropriate treatment of individuals with
HIV/AIDS can prolong the lives of such individuals,
preserve their families and prevent children from be-
coming orphans, and increase productivity of such in-
dividuals by allowing them to lead active lives and
reduce the need for costly hospitalization for treat-
ment of opportunistic infections caused by HIV.
(23) United States nongovernmental organiza-
tions, including faith-based organizations, with expe-
rience in healthcare and HIV/AIDS counseling, have
proven effective in combatting the HIV/AIDS pan-
demic and can be a resource in assisting sub-Saharan
African leaders of traditional, political, business, and
women and youth organizations in their efforts to
provide treatment and care for individuals infected
with HIV/AIDS.
(24) Most of the HIV infected poor of the devel-
oping world die of deadly diseases such as tuber-
culosis and malaria. Accordingly, effective HIV/AIDS
treatment programs should address the growing threat
and spread of tuberculosis, malaria, and other infec-
tious diseases in the developing world.
(25) Law enforcement and military personnel of
foreign countries often have a high rate of prevalence
of HIV/AIDS, and therefore, in order to be effective,
HIV/AIDS awareness, prevention, and education pro-
grams must include education and related services to
such law enforcement and military personnel.
(26) Microenterprise development and other in-
come generation programs assist communities af-
flicted by the HIV/AIDS pandemic and increase the
productive capacity of communities and afflicted
households. Microenterprise programs are also an ef-
fective means to support the productive activities of
healthy family members caring for the sick and or-
phaned. Such programs should give priority to
women infected with the AIDS virus or in HIV/AIDS
affected families, particularly women in high-risk cat-
egories.
(27) The exploding global HIV/AIDS pandemic
has created new challenges for United States bilateral
assistance programs and will require a substantial
increase in the capacity of the United States Agency
for International Development and other agencies of
the United States to manage and monitor bilateral
HIV/AIDS programs and resources. To meet this
challenge, the Agency will need to recruit and retain
appropriate technical expertise in the United States
as well as in foreign countries to help develop and
implement HIV/AIDS strategies in concert with mul-
tilateral agencies, host country governments, and non-
governmental organizations.
(b) SENSE OF CONGRESS.—It is the sense of Congress
that—
(1)(A) combatting the HIV/AIDS pandemic in
countries in sub-Saharan Africa and other developing
countries should be a global effort and include the fi-
nancial support of all developed countries and the co-
operation of governments and the private sector, in-
cluding faith-based organizations; and
(B) the United States should provide additional
funds for multilateral programs and efforts to combat
HIV/AIDS and also seek to leverage public and pri-
vate resources to combat HIV/AIDS on a global basis
through the Global Development Alliance Initiative of
the United States Agency for International Develop-
ment and other public and private partnerships with
an emphasis on HIV/AIDS awareness, education, pre-
vention, and treatment programs;
(2)(A) in addition to HIV/AIDS awareness, edu-
cation, and prevention programs, the United States
Government should make its best efforts to support
programs that safely make available to public and
private entities in countries in sub-Saharan Africa
and other developing countries pharmaceuticals and
diagnostics for HIV/AIDS therapy in order—
(i) to effectively and safely assist such coun-
tries in the delivery of HIV/AIDS therapy phar-
maceuticals through the establishment of ade-
quate health care delivery systems and treatment
monitoring programs; and
(ii) to provide treatment for poor individ-
uals with HIV/AIDS in such countries; and
(B) in carrying out such programs, priority con-
sideration for participation should be given to coun-
tries in sub-Saharan Africa;
(3)(A) combatting the HIV/AIDS pandemic re-
quires that United States Government programs place
a priority on the vulnerable populations at greatest
risk for contracting HIV;
(B) these populations should be determined
through qualitative and quantitative assessments at
the local level by local government, nongovernmental
organizations, people living with HIV/AIDS, and
other relevant sectors of civil society; and
(C) such assessments should be included in na-
tional HIV/AIDS strategies;
(4) the United States should promote efforts to
expand and develop programs that support the grow-
ing number of children orphaned by the HIV/AIDS
pandemic;
(5) in countries where the United States Govern-
ment is conducting HIV/AIDS awareness, prevention,
and education programs, such programs should in-
clude education and related services to law enforce-
ment and military personnel of foreign countries to
prevent and control HIV/AIDS, malaria, and tuber-
culosis;
(6) prevention and treatment for HIV/AIDS
should be a component of a comprehensive inter-
national effort to combat deadly infectious diseases,
including malaria and tuberculosis, and opportun-
istic infections, that kill millions annually in the de-
veloping world;
(7) programs developed by the United States
Agency for International Development to address the
HIV/AID pandemic should preserve personal privacy
and confidentiality, should not include compulsory
HIV/AIDS testing, and should not be discriminatory;
(8)(A) the United States Agency for Inter-
national Development should carry out HIV/AIDS
awareness, prevention, and treatment programs in
conjunction with effective international tuberculosis
and malaria treatment programs and with programs
that address the relationship between HIV/AIDS and
a number of opportunistic diseases that include bac-
terial diseases, fungal diseases, viral diseases and
HIV-associated malignancies, such as Kaposi sar-
coma, lymphoma, and squamous cell carcinoma; and
(B) effective intervention against opportunistic
diseases requires not only the appropriate drug or
other medication for a given medical condition, but
also the infrastructure necessary to diagnose the con-
dition, monitor the intervention, and provide coun-
seling services; and
(9) the United States Agency for International
Development should expand and replicate successful
microenterprise 
programs 
in 
Uganda, 
Zambia,
Zimbabwe, and other African countries that provide
poor families affected by HIV/AIDS with the means
to care for themselves, their children, and orphans;
(10) the United States Agency for International
Development should substantially increase and im-
prove its capacity to manage and monitor HIV/AIDS
programs and resources;
(11) the United States Agency for International
Development must recruit and retain appropriate
technical expertise in the United States as well as in
foreign countries to help develop and implement HIV/
AIDS strategies in conjunction with multilateral
agencies, host country governments, and nongovern-
mental organizations;
(12) the United States Agency for International
Development must strengthen coordination and col-
laboration between the technical experts in its central
and regional bureaus and foreign country missions in
formulating country strategies and implementing
HIV/AIDS programs;
(13) strong coordination among the various
agencies of the United States, including the Depart-
ment of State, the United States Agency for Inter-
national Development, the Department of Health and
Human Services, including the Centers for Disease
Control and the National Institutes of Health, the De-
partment of the Treasury, the Department of Defense,
and other relevant Federal agencies must exist to en-
sure effective and efficient use of financial and tech-
nical resources within the United States Government;
and
(14) to help alleviate human suffering, and en-
hance the dignity and quality of life for patients de-
bilitated by HIV/AIDS, the United States should pro-
mote, both unilaterally and through multilateral ini-
tiatives, the use of palliative and hospice care, and
provide financial and technical assistance to pallia-
tive and hospice care programs, including programs
under which such care is provided by faith-based or-
ganizations.
SEC. 3. ASSISTANCE TO COMBAT HIV/AIDS.
(a) ASSISTANCE.—Section 104(c) of the Foreign As-
sistance Act of 1961 (22 U.S.C. 2151b(c)) is amended—
(1) by striking paragraphs (4) through (6); and
(2) by inserting after paragraph (3) the fol-
lowing:
‘‘(4)(A) Congress recognizes that the alarming spread
of HIV/AIDS in countries in sub-Saharan Africa and other
developing countries is a major global health, national secu-
rity, and humanitarian crisis. Accordingly, the United
States and other developed countries should provide assist-
ance to countries in sub-Saharan Africa and other devel-
oping countries to control this crisis through HIV/AIDS
prevention, treatment, monitoring, and related activities,
particularly activities focused on women and youth, includ-
ing mother-to-child transmission prevention strategies.
‘‘(B)(i) The Administrator of the United States Agency
for International Development is authorized to provide as-
sistance to prevent, treat, and monitor HIV/AIDS, and
carry out related activities, in countries in sub-Saharan Af-
rica and other developing countries.
‘‘(ii) It is the sense of Congress that the Administrator
should provide an appropriate level of assistance under
clause (i) through nongovernmental organizations in coun-
tries in sub-Saharan Africa and other developing countries
affected by the HIV/AIDS pandemic.
‘‘(iii) The Administrator shall coordinate the provision
of assistance under clause (i) with the provision of related
assistance by the Joint United Nations Programme on HIV/
AIDS (UNAIDS), the United Nations Children’s Fund
(UNICEF), the World Health Organization (WHO), the
United Nations Development Programme (UNDP), other
appropriate international organizations, national, state,
and local governments of foreign countries, and other ap-
propriate governmental and nongovernmental organiza-
tions.
‘‘(C) Assistance provided under subparagraph (B)
shall, to the maximum extent practicable, be used to carry
out the following activities:
‘‘(i) Prevention of HIV/AIDS through activities
including—
‘‘(I) education, voluntary testing, and coun-
seling (including the incorporation of confiden-
tiality protections with respect to such testing
and counseling), including integration of such
programs into women’s and children’s health
programs; and
‘‘(II) assistance through nongovernmental
organizations, including faith-based organiza-
tions, particularly those organizations that uti-
lize both professionals and volunteers with ap-
propriate skills and experience, to establish and
implement culturally appropriate HIV/AIDS
education and prevention programs.
‘‘(ii) The treatment and care of individuals with
HIV/AIDS, including—
‘‘(I) assistance to establish and implement
programs to strengthen and broaden indigenous
health care delivery systems and the capacity of
such systems to deliver HIV/AIDS pharma-
ceuticals and otherwise provide for the treatment
of individuals with HIV/AIDS, including clin-
ical training for indigenous organizations and
health care providers;
‘‘(II) assistance aimed at the prevention of
transmission of HIV/AIDS from mother to child,
including medications to prevent such trans-
mission; and
‘‘(III) assistance to strengthen and expand
hospice and palliative care programs to assist
patients debilitated by HIV/AIDS, their families,
and the primary caregivers of such patients, in-
cluding programs that utilize faith-based organi-
zations.
‘‘(iii) The monitoring of programs, projects, and
activities carried out pursuant to clauses (i) and (ii),
including—
‘‘(I) monitoring to ensure that adequate
controls are established and implemented to pro-
vide HIV/AIDS pharmaceuticals and other ap-
propriate medicines to poor individuals with
HIV/AIDS; and
‘‘(II) appropriate evaluation and surveil-
lance activities.
‘‘(iv) 
The 
conduct 
of 
related 
activities,
including—
‘‘(I) the care and support of children who
are orphaned by the HIV/AIDS pandemic, in-
cluding services designed to care for orphaned
children in a family environment which rely on
extended family members;
‘‘(II) improved infrastructure and institu-
tional capacity to develop and manage edu-
cation, prevention, and treatment programs, in-
cluding the resources to collect and maintain ac-
curate HIV surveillance data to target programs
and measure the effectiveness of interventions;
‘‘(III) vaccine research and development
partnership programs with specific plans of ac-
tion to develop a safe, effective, accessible, pre-
ventive HIV vaccine for use throughout the
world; and
‘‘(IV) the development and expansion of fi-
nancially-sustainable microfinance institutions
and other income generation programs that
strengthen the economic and social viability of
communities afflicted by the HIV/AIDS pan-
demic, including support for the savings and
productive capacity of affected poor households
caring for orphans.
‘‘(D)(i) Not later than January 31 of each calendar
year, the Administrator shall submit to Congress an annual
report on the implementation of this paragraph for the
prior fiscal year.
‘‘(ii) Such report shall include—
‘‘(I) a description of efforts made to implement
the policies set forth in this paragraph;
‘‘(II) a description of the programs established
pursuant to this paragraph and section 4 of the Glob-
al Access to HIV/AIDS Prevention, Awareness, Edu-
cation, and Treatment Act of 2001; and
‘‘(III) a detailed assessment of the impact of pro-
grams established pursuant to this paragraph, includ-
ing the effectiveness of such programs in reducing the
spread of HIV infection, particularly in women and
girls, in reducing HIV transmission from mother to
child, in reducing mortality rates from HIV/AIDS,
and the progress toward improving health care deliv-
ery systems and infrastructure to ensure increased ac-
cess to care and treatment.
‘‘(iii) The Administrator shall consult with the Global
Health Advisory Board established under section 6 of the
Global Access to HIV/AIDS Prevention, Awareness, Edu-
cation, and Treatment Act of 2001 in the preparation of
the report under clause (i) and on other global health activi-
ties carried out by the United States Agency for Inter-
national Development.
‘‘(E)(i) There is authorized to be appropriated to the
President to carry out this paragraph $560,000,000 for fis-
cal year 2002.
‘‘(ii) Not more than six percent of the amount appro-
priated pursuant to the authorization of appropriations
under clause (i) for fiscal year 2002, and not more than
four percent of the amount made available to carry out this
paragraph for any subsequent fiscal year, may be used for
the administrative expenses of the Agency in carrying out
this paragraph.
‘‘(iii) Amounts appropriated pursuant to the author-
ization of appropriations under clause (i) are in addition
to amounts otherwise available for such purposes and are
authorized to remain available until expended.
‘‘(F) In this paragraph:
‘‘(i) The term ‘HIV’ means infection with the
human immunodeficiency virus.
‘‘(ii) The term ‘AIDS’ means acquired immune
deficiency syndrome.’’.
(b) AVAILABILITY OF ASSISTANCE UNDER SECTION
104(c).—Section 104(c) of the Foreign Assistance Act of
1961 (22 U.S.C. 2151b(c)) is amended—
(1) by redesignating paragraph (7) as para-
graph (5); and
(2) by adding at the end the following:
‘‘(6) Assistance made available under any paragraph
of this subsection, and assistance made available under
chapter 4 of part II of this Act to carry out the purposes
of any paragraph of this subsection, may be made available
notwithstanding any other provision of law.’’.
SEC. 4. ASSISTANCE FOR PROCUREMENT AND DISTRIBU-
TION OF HIV/AIDS PHARMACEUTICALS AND
RELATED MEDICINES.
(a) ASSISTANCE.—The Administrator of the United
States Agency for International Development shall provide
assistance to countries in sub-Saharan Africa and other de-
veloping countries for—
(1) the procurement of HIV/AIDS pharma-
ceuticals, anti-viral therapies, and other appropriate
medicines; and
(2) the distribution of such HIV/AIDS pharma-
ceuticals, anti-viral therapies, and other appropriate
medicines to qualified national, regional, or local or-
ganizations for the treatment of individuals with
HIV/AIDS in accordance with appropriate HIV/
AIDS testing and monitoring requirements and for
the prevention of transmission of HIV/AIDS from
mother to child.
(b) ADDITIONAL AUTHORITY.—The authority con-
tained in section 104(c)(6) of the Foreign Assistance Act
of 1961, as amended by section 3(b) of this Act, shall apply
to assistance made available under subsection (a).
(c) AUTHORIZATION OF APPROPRIATIONS.—There is
authorized to be appropriated to the President to carry out
this section $50,000,000 for fiscal year 2002.
SEC. 5. INTERAGENCY TASK FORCE ON HIV/AIDS.
(a) ESTABLISHMENT.—The President shall establish
an interagency task force (hereafter referred to as the ‘‘task
force’’) to ensure coordination of all Federal programs re-
lated to the prevention, treatment, and monitoring of HIV/
AIDS in foreign countries.
(b) DUTIES.—The duties of the task force shall
include—
(1) reviewing all Federal programs related to the
prevention, treatment, and monitoring of HIV/AIDS
in foreign countries to ensure proper coordination
and compatibility of activities and policies of such
programs;
(2) exchanging information regarding design
and impact of such programs to ensure that the
United States Government can catalogue the best pos-
sible practices for HIV/AIDS prevention, treatment,
and monitoring and improve the effectiveness of such
programs in the countries in which they operate; and
(3) fostering discussions with United States and
foreign nongovernmental organizations to determine
how United States Government programs can be im-
proved, including by engaging in a dialogue with the
Global Health Advisory Board established under sec-
tion 6 of this Act.
(c) MEMBERSHIP.—
(1) COMPOSITION.—The task force shall be com-
posed of the Secretary of State, the Administrator of
the United States Agency for International Develop-
ment, the Secretary of Heath and Human Services,
the Director of the National Institutes of Health, the
Director of the Centers for Disease Control, the Sec-
retary of Defense, and the head of any other agency
that the President determines is appropriate.
(2) CHAIRPERSON.—The Secretary of State shall
serve as chairperson of the task force.
(d) PUBLIC MEETINGS.—At least once each calendar
year, the task force shall hold a public meeting in order
to afford an opportunity for any person to present views
regarding the activities of the United States Government
with respect to the prevention, treatment, and monitoring
of HIV/AIDS in foreign countries. The Secretary of State
shall maintain a record of each meeting and shall make
the record available to the public.
(e) AVAILABILITY OF FUNDS.—Amounts made avail-
able for a fiscal year pursuant to section 104(c)(4)(E)(ii)
of the Foreign Assistance Act of 1961, as amended by sec-
tion 3(a) of this Act, are authorized to be made available
to carry out this section for such fiscal year.
SEC. 6. GLOBAL HEALTH ADVISORY BOARD.
(a) ESTABLISHMENT.—There is established a perma-
nent Global Health Advisory Board (hereafter referred to
as the ‘‘Board’’) to assist the President and other Federal
officials, including the Secretary of State and the Adminis-
trator of the United States Agency for International Devel-
opment, in the administration and implementation of
United States international health programs, particularly
programs relating to the prevention, treatment, and moni-
toring of HIV/AIDS.
(b) DUTIES.—
(1) IN GENERAL.—The Board shall serve as a li-
aison between the United States Government and pri-
vate and voluntary organizations, other nongovern-
mental organizations, and academic institutions in
the United States that are active in international
health issues, particularly prevention, treatment, and
care with respect to HIV/AIDS and other infectious
diseases.
(2) SPECIFIC
ACTIVITIES.—In carrying out
paragraph (1), the Board—
(A) shall provide advice to the United
States Agency for International Development
and other Federal agencies on health and man-
agement issues relating to foreign assistance in
which both the United States Government and
private and voluntary organizations participate;
(B) shall provide advice on the formulation
of basic policy, procedures, and criteria for the
review, selection, and monitoring of project pro-
posals for United States Government inter-
national health programs and for the establish-
ment of transparency in the provision and im-
plementation of grants made under such pro-
grams;
(C) shall provide advice on the establish-
ment of evaluation and monitoring programs to
measure the effectiveness of United States Gov-
ernment international health programs, includ-
ing standards and criteria to assess the extent to
which programs have met their goals and objec-
tives and the development of indicators to track
progress of specific initiatives;
(D) shall review and evaluate the overall
health strategy for United States bilateral assist-
ance for each country receiving significant
United States bilateral assistance in the health
sector;
(E) shall recommend which developing
countries could benefit most from programs car-
ried out under United States Government inter-
national health programs; and
(F) shall assess the impact and effectiveness
of programs carried out under section 104(c)(4)
of the Foreign Assistance Act of 1961, as amend-
ed by section 3(a) of this Act, in meeting the ob-
jectives set out in the HIV/AIDS country strat-
egy established by the United States Agency for
International Development.
(c) MEMBERSHIP.—
(1) COMPOSITION.—The Board shall be composed
of 12 members—
(A)(i) all of whom shall have a substantial
expertise and background in international health
research, policy, or management, particularly in
the area of prevention, treatment, and care with
respect to HIV/AIDS and other infectious dis-
eases; and
(ii) of whom at least one member shall be
an expert on women’s and children’s health
issues; and
(B) of whom—
(i) three members shall be individuals
from academic institutions;
(ii) five members shall be individuals
from nongovernmental organizations active
in international health programs, particu-
larly HIV/AIDS prevention, treatment and
monitoring programs in foreign countries,
of which not more than two members may
be from faith-based organizations;
(iii) two members shall be individuals
from health policy and advocacy institutes;
and
(iv) two members shall be individuals
from private foundations that make sub-
stantial contributions to global health pro-
grams.
(2) APPOINTMENT.—The individuals referred to
in paragraph (1) shall be appointed by the President,
after consultation with the chairman and ranking
member of the Committee on International Relations
of the House of Representatives and the Committee on
Foreign Relations of the Senate.
(3) TERMS.—
(A) IN GENERAL.—Except as provided in
subparagraph (B), each member shall be ap-
pointed for a term of two years and no member
or organization shall serve on the Advisory
Board for more than two consecutive terms.
(B) TERMS
OF
INITIAL
APPOINTEES.—As
designated by the President at the time of ap-
pointment, of the members first appointed—
(i) six members shall be appointed for
a term of three years; and
(ii) six members, to the extent prac-
ticable equally divided among the categories
described in clauses (i) through (iv) of para-
graph (1)(B), shall be appointed for a term
of two years.
(4) CHAIRPERSON.—At the first meeting of the
Board in each calendar year, a majority of the mem-
bers of the Commission present and voting shall elect,
from among the members of the Board, an individual
to serve as chairperson of the Board.
(d) TRAVEL EXPENSES.—Each member of the Board
shall receive travel expenses, including per diem in lieu of
subsistence, in accordance with applicable provisions under
subchapter I of chapter 57 of title 5, United States Code.
(e) AVAILABILITY OF FUNDS.—Amounts made avail-
able for a fiscal year pursuant to section 104(c)(4)(E)(ii)
of the Foreign Assistance Act of 1961, as amended by sec-
tion 3(a) of this Act, are authorized to be made available
to carry out this section for such fiscal year.
SEC. 7. AUTHORIZATION OF APPROPRIATIONS FOR MULTI-
LATERAL EFFORTS TO PREVENT, TREAT, AND
MONITOR HIV/AIDS.
(a) AUTHORIZATION.—There is authorized to be ap-
propriated to the President $750,000,000 for fiscal year
2002 for United States contributions to a global health fund
or other multilateral efforts to prevent, treat, and monitor
HIV/AIDS in countries in sub-Saharan Africa and other
developing countries, including efforts to provide hospice
and palliative care for individuals with HIV/AIDS.
(b) CHARACTERISTICS OF GLOBAL HEALTH FUND.—
It is the sense of Congress that United States contributions
should be provided to a global health fund under subsection
(a) only if the fund—
(1) is a public-private partnership that includes
participation of, and seeks contributions from, gov-
ernments, foundations, corporations, nongovernmental
organizations, organizations that are part of the
United Nations system, and other entities or individ-
uals;
(2)(A) includes donors, recipient countries, civil
society, and other relevant parties in the governance
of the fund; and
(B) contains safeguards against conflicts of in-
terest in the governance of the fund by the individuals
and entities described in subparagraph (A);
(3) supports targeted initiatives to address HIV/
AIDS, tuberculosis, and malaria through an inte-
grated approach that includes prevention interven-
tions, care and treatment programs, and infrastruc-
ture capacity-building;
(4) permits strategic targeting of resources to ad-
dress needs not currently met by existing bilateral
and multilateral efforts and includes separate sub-ac-
counts for different activities allowing donors to des-
ignate funds for specific categories of programs and
activities;
(5) reserves a minimum of 5 percent of its grant
funds to support scientific or medical research in con-
nection with the projects it funds in developing coun-
tries;
(6) provides public disclosure with respect to—
(A) the membership and official proceedings
of the mechanism established to manage and dis-
burse amounts contributed to the fund; and
(B) grants and projects supported by the
fund;
(7) authorizes and enforces requirements for the
periodic financial and performance auditing of
projects and makes future funding conditional upon
the results of such audits; and
(8) provides public disclosure of the findings of
all financial and performance audits of the fund.
SEC. 8. DEFINITION.
In this Act:
(1) HIV.—The term ‘‘HIV’’ means infection
with the human immunodeficiency virus.
(2) AIDS.—The term ‘‘AIDS’’ means acquired
immune deficiency syndrome.
Union Calendar No. 78
107TH CONGRESS
1ST SESSION
H. R. 2069
[Report No. 107–137]
A BILL
To amend the Foreign Assistance Act of 1961 to
authorize assistance to prevent, treat, and mon-
itor HIV/AIDS in sub-Saharan African and other
developing countries.
JULY 12, 2001
Reported with an amendment, committed to the Com-
mittee of the Whole House on the State of the Union,
and ordered to be printed